Evandro de Azambuja, MD, PhD

Evandro de Azambuja, Breast cancer specialist @JulesBordet.
BSMO President 2023-2026.

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Modest improvement in PFS with pembro + chemo for pts with HR+ PD-L1 + MBC
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO

[ESMO - Eur. Oncology @myESMO]

#ESMO26: Pembrolizumab plus chemotherapy reduced the risk of PFS by 26% in PD-L1-positive, HR-positive #AdvancedBreastCancer after failure on endocrine therapy in the phase III KEYNOTE-B49

🔗 https://t.co/EySupVsvmA

#ClinicalTrial #BreastCancer #InsightsbyESMO
@PTarantinoMD

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Post-monarch continue to show improvement in PFS and numerically (NS) OS
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO @KalinskyKevin

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

FES-PET defined heterogeneity is associated with long-term survival
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO @ALEDIGNUS12

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Baseline HER2 Pet serve as a powerful rule-out for TDXD response in MBC
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Giredestrant + everolimus improves PFS compared with ET + everolimus irrespective of of ESR1 variants, tumor fraction, poor prognosis subgroups
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO @stolaney1

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Anbenitamab + HB1801 has better PFS than THP as first line therapy (control arm did poorly 14.3 mos)
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Dato-dxd shows an intracranial ORR of 62.5 % and median CNS PFS of 9.5 mos in pts with brain metastases (TROPiON-Breast02)
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@esmo @RebeccaDSing

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Atimorciclib + fulvestrant improves PFS compared to TPC in pts progressing on prior CDK4/6i. More grade 3 or higher TRAE
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Keynote B49 -chemo + pembro vs chemo in HR+ PD-L1 +: better PFS but only 0.7 mos and no OS benefit - no ADC comparator
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO @Annals_Oncology

[ESMO - Eur. Oncology @myESMO]

#ESMO26: Final results from the TALENT #ClinicalTrial show low pathological complete response rates with the antibody–drug conjugate (#ADC) trastuzumab deruxtecan in HR-positive, HER2-low #EarlyBreastCancer, as discussed by @breastDoktor #InsightsbyESMO
➡️ https://t.co/pEwVYrWK4C

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Interesting data on MRI and correlation with pCR in destiny-breast 11
TDXd followed by THP demonstrated a rapid and deeper tumor response.
Important to complete the full NA regimen
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Giredastrant improved IDFS and had a better tolerability (less arthralgia) compared to AI
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO @GustavoWerutsky

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Iza-bren improves PFS compared to standard chemo in pts with HR+ HER2 neg MBC after 1-2 lines of CT for metastatic disease
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

6-year results of Natalee (ribociclib): improvements in OS, BCSS, iDFS, DRFS - some subgroups analyses still required

#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO @Annals_Oncology

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Final analysis of NSABP B-42 - mFu 15.9 years - extended ET continue to improve DFS, BCFi, distant recurrences. Similar OS and osteoporotic fractures and TVE
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

TQB2102 imporoves PFS in chemo naive HR + HER2 low MBC - OS trend - low ILD rate
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Trastuzumab rezetecan improves PFS in chemo-naive and chemo pretreated HER2 low MBC - low incidence of ILD
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO @JAMA_current

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Low activity of TDXD in HER2 low ER+ EBC
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

✨Look who got a glow up! ✨ New @myESMO logo unveiled. #ESMO26 @OncoAlert

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Congratulations @Piuchagarrido for the Women for Oncology award
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO